XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Charges
 9 Months Ended
Sep. 30, 2015
Restructuring and Related Activities [Abstract]  
Restructuring Charges
9. Restructuring Charges
 
Restructuring charges incurred during the nine months ended September 30, 2015 primarily consist of severance and other post-termination benefit costs resulting from the cost reduction program implemented by the Company in January 2015. These activities primarily consisted of a 20% reduction of the Company’s workforce. A summary of the activity is presented below:
 
(in thousands)
  
Contract
termination
 costs - R&D
    
Salaries and
 benefits -
R&D
    
Salaries and
 benefits -
G&A
    
Total
  
Balance as of December 31, 2014
  
$
1,185
    
$
—
    
$
—
    
$
1,185
  
Accrued
    
—
      
522
      
82
      
604
  
Paid
    
(479
)
    
(257
)
    
—
      
(736
)
Balance as of March 31, 2015
  
$
706
    
$
265
    
$
82
    
$
1,053
  
Accrued
    
—
      
57
      
122
      
179
  
Paid
    
(135
)
    
(142
)
    
—
      
(277
)
Balance as of June 30, 2015
  
$
571
    
$
180
    
$
204
    
$
955
  
Accrued
    
—
      
—
      
—
      
—
  
Adjustments
    
(78
)
    
—
      
—
      
(78
)
Paid
    
(493
)
    
(148
)
    
(136
)
    
(777
)
Balance as of September 30, 2015
  
$
-
    
$
32
    
$
68
    
$
100
  

As disclosed in Note 8, during the nine months ended September 30, 2015, the Company recorded stock based compensation expense of $479,000 related to the fair value of stock options of former employees which were modified such that they did not expire upon termination. The Company classified $95,000 and $384,000 as general and administrative expenses and research and development expenses, respectively.

As of December 31, 2014, the Company accrued certain contract termination costs of $1.2 million relating to manufacturing activity that no longer had identifiable future benefit to the Company. During the second quarter ended June 30, 2015, accrued liabilities were reduced by $312,000 related to research-related manufacturing expenses incorrectly recorded in 2014. The Company analyzed and assessed the effect of this adjustment on previously reported annual and interim periods in 2014 as well as the impact of the benefit from the reversal of these expenses to the results of operations for the nine months ended September 30, 2015. Following this analysis and taking into account both quantitative and qualitative factors, the Company believes that the uncorrected out-of-period costs are not material to the respective periods in which the errors occurred.